-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GTaz0XvFpuIRAF62GJOfXvUXLY0awPk1GdCK4t0QYCqouTDEUoRvlNNt9CGVQ40I FP1p6CIfs6qZc3s3sESAIQ== 0000882377-03-001566.txt : 20031008 0000882377-03-001566.hdr.sgml : 20031008 20031008095543 ACCESSION NUMBER: 0000882377-03-001566 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031008 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CALYPTE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000899426 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 061226727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-50235 FILM NUMBER: 03932593 BUSINESS ADDRESS: STREET 1: 1265 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502- BUSINESS PHONE: 5107495100 MAIL ADDRESS: STREET 1: 1265 HARBOR BAY PKWY CITY: ALAMEDA STATE: CA ZIP: 94502 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MARR TECHNOLOGIES BV CENTRAL INDEX KEY: 0001262853 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NEDTHERLANDS STATE: P7 ZIP: 00000 BUSINESS PHONE: 0110031206625501 MAIL ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NETHERLANDS STATE: P7 ZIP: 00000 SC 13D/A 1 d178984.txt CALYPTE BIOMEDICAL CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 CALYPTE BIOMEDICAL CORPORATION (Name of Issuer) COMMON STOCK $.03 PAR VALUE (Title of Class of Securities) 131722100 (CUSIP Number) WALTER G. VAN DORN, JR., ESQ. THACHER PROFFITT & WOOD LLP TWO WORLD FINANCIAL CENTER NEW YORK, NEW YORK 10281 (212) 912-7400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 30, 2003 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of Rule13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 4 Pages) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. CUSIP NO. 131722100 SCHEDULE 13 D PAGE 2 OF 5 PAGES The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 131722100 SCHEDULE 13 D PAGE 3 OF 5 PAGES 1 NAME OF REPORTING PERSON: Marr Technologies BV S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (voluntary): _________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (see instructions) (b) [ ] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS (see instructions) WC ________________________________________________________________________________ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION The Netherlands ________________________________________________________________________________ NUMBER OF 7 SOLE VOTING POWER SHARES 38,915,151 (See Item 5) BENEFICIALLY __________________________ OWNED BY 8 SHARED VOTING POWER EACH 0 REPORTING __________________________ PERSON 9 SOLE DISPOSITIVE POWER WITH 38,915,151 (See Item 5) __________________________ 10 SHARED DISPOSITIVE POWER 0 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 38,915,151 (See Item 5) ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [ ] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 46.75% (See Item 5) ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON (see instructions) CO CUSIP NO. 131722100 SCHEDULE 13 D PAGE 4 OF 5 PAGES STATEMENT FOR SCHEDULE 13D This Amendment No. 2 to Schedule 13D relates to common stock of Calypte Biomedical Corporation (the "Company"). This Amendment No. 2 amends the initial statement on Schedule 13D ("Initial Statement") filed with the Securities and Exchange Commission on September 8, 2003 by Marr Technologies BV ("MTBV") and Amendment No. 1 to the Initial Statement ("Amendment No. 1") filed with the Securities and Exchange Commission on October 1, 2003 by MTBV. The Initial Statement and Amendment No. 1 are amended as follows: Item 3. Source and Amount of Funds or Other Consideration MTBV purchased 1,200,000 shares of common stock of the Company over a period beginning on July 25, 2003 and ending on September 30, 2003, which were not previously reported in the Initial Statement or Amendment No. 1. MTBV spent $539,178 in making such purchases. MTBV funded such purchases from its working capital. Item 5. Interest in Securities of the Issuer MTBV has sole voting and dispositive power with respect to 38,915,151 shares, or approximately 46.75% of the 83,248,301 shares of common stock of the Company outstanding. The following table sets forth a description of the transactions effected by MTBV in the class of securities reported herein in the past 60 days. Date Number of Shares Price Per Share - ---- ---------------- --------------- 7/25/03 500,000 $0.1225 7/29/03 8,333,333 $0.30 8/14/03 800,000 $0.1506 8/15/03 800,000 $0.1414 8/17/03 1,300,000 $0.145 8/21/03 1,200,000 $0.1502 8/25/03 400,000 $0.1834 8/27/03 50,000 $0.1950 8/28/03 20,000,000 $0.50 9/01/03 5,181,818 $0.11 9/01/03 50,000 $0.5585 9/30/03 300,000 $1.3180 Such shares were purchased in a combination of privately negotiated transactions and open market transactions effected on the Over the Counter Bulletin Board. The shares acquired on September 1, 2003 were the result of conversion to common stock of a convertible debenture dated September 1, 2003. CUSIP NO. 131722100 SCHEDULE 13 D PAGE 5 OF 5 PAGES SIGNATURES After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true and complete. Dated: October 7, 2003 MARR TECHNOLOGIES BV By: /s/ Christian Strik ------------------------ Name: Christian Strik Title: Director -----END PRIVACY-ENHANCED MESSAGE-----